MDCX Stock — Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd. Common Stock (MDCX)

Updated October 16, 2026.

MDCX is a Stock. Total return is 464185.7% over the past 10.7 years, 463811.3 points ahead of SPY at 374.4%.

Medicus Pharma Ltd. is a biotech/life sciences company developing clinical therapeutic programs in the United States, with a focus on SKNJCT-003, a candidate in Phase 2 study for basal cell carcinoma treatment, and a strategic collaboration with the Gorlin Syndrome Alliance. The company does not currently have an established distribution frequency. This security may appeal to investors seeking exposure to early-stage pharmaceutical development and clinical-stage biotech companies.

MDCX performance versus SPY

Price and return data through 2026-10-16.

Total return is 464185.7% over the past 10.7 years, 463811.3 points ahead of SPY at 374.4%. Over the past year its total return — price change plus distributions reinvested — is -97.3%. Its deepest 1-year drawdown was 97.7%.

MDCX key facts

Asset type

Stock

Asset class

Equity

Inception date

02/03/2016

Distribution frequency

None

Last close

$3.25 (as of 2026-10-16)

Market cap

$4,661,150

Average volume

28178.0

Beta

-0.298

Payout ratio

0.0%

EPS

$-119.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MDCX risks and drawbacks

The deepest 1-year drawdown on record here is 97.7%.

Who may consider MDCX — and who may not

It is a weaker fit for investors who need monthly cash flow (MDCX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MDCX

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions